Saturday 17 October 2026
Export ALUR’s income statement to Excel — free account
Allurion Technologies, Inc.
ALUR Healthcare Medical Devices
Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024. In the quarter to March 2026, revenue fell 47.2%, EPS fell 46.5% and free cash flow grew 66.0%, each against the same quarter a year earlier.
0.48
0.12
−20.00%
Follow ALUR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z-Score |
(29.57) | (13.24) | (7.06) | (5.04) | — | — | — |
P/S ratio |
0.04 | 0.05 | 0.16 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(76.26) | (31.44) | (17.76) | (17.13) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Beneish M-Score |
(2.91) | 2.02 | (4.23) | — | — | — | — |
P/Operating CF |
(0.12) | (0.12) | (0.40) | (1.16) | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Sales |
4.36 | 1.90 | 0.54 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(2.29) | (1.44) | (0.45) | (1.42) | — | — | — |
EV/FCF |
(2.25) | (1.42) | (0.44) | (1.38) | — | — | — |
Quick Ratio |
0.24 | 1.19 | 0.86 | 0.49 | 2.26 | 0.15 | — |
Current Ratio |
0.33 | 1.44 | 0.99 | 0.57 | 4.34 | 0.15 | — |
Net Debt/EBITDA |
0.19 | (0.41) | (0.01) | (1.57) | (0.25) | (23.63) | — |
Debt/Assets |
0.00% | 108.83% | 53.89% | 109.91% | 0.16% | 51.52% | 0.00% |
Debt/Equity |
0.00 | (0.46) | (0.54) | (1.75) | (0.02) | 8.59 | — |
Asset Turnover |
0.63 | 0.61 | 0.87 | 0.14 | 0.00 | 0.00 | — |
Operating CF/Net income |
1.01 | 5.88 | 0.76 | 1.16 | (0.36) | 0.00 | — |
Capex/Depreciation |
0.00 | (0.61) | (2.15) | (1.73) | — | — | — |
Interest Coverage |
— | (22.17) | (7.48) | (7.23) | (44.81) | — | — |
| 37.06% | 9.64% | 163.14% | 86.65% | (18.74%) | 0.00% | — | |
| (118.37%) | (13.77%) | (137.33%) | (8.88%) | 1.33% | (3.15%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | (121.52%) | 0.00% | (2.28%) | — |
Return on Tangible Assets |
118.40% | (66.88%) | (3,048.85%) | 135.04% | 464.50% | 1.98% | — |
Average Days of Receivables |
94.69 | 81.09 | 124.20 | 166.81 | — | — | — |
Research and Development Expense of Revenue |
49.71% | 54.09% | 51.80% | 26.42% | — | — | — |
Selling, General and Administrative Expense of Revenue |
211.14% | 169.21% | 173.72% | 102.43% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
20.66% | 9.52% | 15.63% | 0.68% | — | — | — |
Graham Net Nets |
(129.50) | (51.90) | (9.34) | (2.22) | — | — | — |
Graham Number |
444.06 | 749.75 | 3,906.89 | 2,306.93 | — | — | — |
Earnings Yield |
(4,645.87%) | (446.76%) | (1,023.20%) | (207.73%) | — | — | — |
Free Cash Flow Yield |
(4,774.50%) | (2,662.92%) | (783.15%) | (267.16%) | — | — | — |
Revenue per Share |
30.26 | 214.21 | 563.40 | 894.30 | 0.00 | 0.00 | — |
Operating CF per Share |
(57.51) | (282.19) | (674.20) | (654.33) | (36.62) | 0.00 | — |
Capex per Share |
0.00 | (4.08) | (16.92) | (21.59) | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(57.51) | (286.26) | (691.13) | (675.92) | (36.62) | 0.00 | — |
Cash per Share |
10.75 | 102.60 | 400.81 | 107.03 | 14.76 | 0.94 | — |
Shareholders Equity per Share |
(153.37) | (520.20) | (751.29) | (450.06) | (1,084.94) | 0.40 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(153.37) | (520.20) | (751.29) | (450.06) | (1,084.94) | 0.40 | — |
Free Cash Flow |
(28.95) | (42.91) | (65.59) | (48.53) | (2.08) | 0.00 | — |
Working Capital |
(25.65) | 8.29 | (0.61) | (32.48) | 1.24 | (0.26) | — |
Capital Expenditures |
— | (0.61) | (1.61) | (1.55) | — | — | — |
Net Current Asset Value |
(80.17) | (83.63) | (78.19) | (40.30) | (924.07) | (0.26) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.00 | 0.02 | 0.03 | 0.02 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||
Depreciation/Fixed assets |
0.72 | 0.40 | 0.22 | 0.38 | — | — | — |
Cash ROIC |
40.33% | 159.59% | (1,218.43%) | (152.45%) | 3.50% | 0.00% | — |
Accounts Receivable Turnover |
2.75 | 2.54 | 2.25 | 0.00 | — | — | — |
Accounts Payable Turnover |
1.12 | 1.25 | 1.48 | 4.64 | 0.00 | 0.00 | — |
Inventory Turnover |
1.86 | 2.22 | 2.39 | 0.00 | — | — | — |
Average Days of Payables |
230.13 | 226.15 | 316.49 | 157.23 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
172.21 | 117.00 | 188.17 | 104.61 | — | — | — |
Average Receivables |
5.54 | 12.66 | 23.77 | — | — | — | — |
Average Payables |
5.07 | 8.48 | 8.09 | 2.91 | 0.06 | 0.06 | — |
Average Inventory |
3.04 | 4.79 | 5.02 | — | — | — | — |
Average Assets |
24.29 | 52.26 | 61.54 | 457.77 | 432.25 | 0.17 | — |
Average Common Equity |
(77.58) | (74.64) | (51.81) | (46.92) | (30.75) | 400.50 | — |
Columns are period end dates